Literature DB >> 35788872

A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor.

Guiyin Li1,2, Wei Chen1, Danhong Mi1, Bo Wang1, HaiMei Li1, Guangxiong Wu1, Ping Ding3, Jintao Liang4, Zhide Zhou5.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths in China. Glypican-3 (GPC3) is a specific antigen related to HCC, which is widely used in clinical detection as a reliable marker of HCC. In this paper, a highly sensitive homogeneous apatasensor was designed for GPC3 detection based on fluorescence resonance energy transfer (FRET) where the GPC3 aptamer labelled gold carbon dots (AuCDs-GPC3Apt) are used as a donor and magnetic graphene oxide (Fe3O4/GO) nanosheets are used as an acceptor. A one-step hydrothermal method was used to synthesize AuCDs to provide sufficient fluorescence. The FRET phenomenon exists between AuCDs-GPC3Apt and Fe3O4/GO, which weakens the fluorescence intensity of the whole system. When the target GPC3 is added to the FRET system, the fluorescent AuCDs-GPC3Apt binds to the GPC3 and forms a folded structure, which leads to AuCDs-GPC3Apt separation from Fe3O4/GO nanosheets. The Fe3O4/GO is then magnetically separated so that the fluorescence of free labelled AuCDs-GPC3Apt is restored. Under the optimum conditions, the fluorescence recovery rate is linearly correlated with the concentration of GPC3 (5-100 ng·mL-1) and the detection limit is 3.01 ng·mL-1 (S/N = 3). This strategy shows recoveries from 98.76 to 101.29% in real human serum samples and provides an immediate and effective detection method for the quantification of GPC3 with great potential applications for early diagnosis of HCC. A sensitive homogeneous FRET-based apatasensor was designed for GPC3 detection where the AuCDs-GPC3Apt is a donor and Fe3O4/GO nanosheets are an acceptor. The GPC3 fluorescent aptasensor combines wider output range with low cost, high specificity, and good anti-interference.
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fluorescence aptasensor; Fluorescence resonance energy transfer; Glypican-3; Gold carbon dots; Magnetic graphene oxide

Mesh:

Substances:

Year:  2022        PMID: 35788872     DOI: 10.1007/s00216-022-04201-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.478


  29 in total

Review 1.  Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.

Authors:  Fubo Zhou; Wenting Shang; Xiaoling Yu; Jie Tian
Journal:  Med Res Rev       Date:  2017-06-16       Impact factor: 12.944

Review 2.  Aptamer based recognition of cancer cells: Recent progress and challenges in bioanalysis.

Authors:  Houman Kholafazad Kordasht; Mohammad Hasanzadeh
Journal:  Talanta       Date:  2020-07-24       Impact factor: 6.057

Review 3.  Long-Term Survival and Prognostic Factors of Pulmonary Metastasectomy in Liver Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chong Wang; Lei Yang; Zikun Liang; Yaodong Liu; Shuku Liu
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

Review 4.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

5.  Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis.

Authors:  Junjie Huang; Veeleah Lok; Chun Ho Ngai; Cedric Chu; Harsh K Patel; Viveksandeep Thoguluva Chandraseka; Lin Zhang; Ping Chen; Shanjuan Wang; Xiang-Qian Lao; Lap Ah Tse; Wanghong Xu; Zhi-Jie Zheng; Martin C S Wong
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

Review 6.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 7.  Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Authors:  Peter R Galle; Friedrich Foerster; Masatoshi Kudo; Stephen L Chan; Josep M Llovet; Shukui Qin; William R Schelman; Sudhakar Chintharlapalli; Paolo B Abada; Morris Sherman; Andrew X Zhu
Journal:  Liver Int       Date:  2019-09-11       Impact factor: 5.828

8.  Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.

Authors:  Chunmei Xie; Christian Tiede; Xuanyi Zhang; Congrong Wang; Zhixiong Li; Xiao Xu; Michael J McPherson; Darren C Tomlinson; Weiwen Xu
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 9.  Can glypican-3 be a disease-specific biomarker?

Authors:  Chaolei Chen; Xiaomin Huang; Zhaojian Ying; Dengmin Wu; Yani Yu; Xiangdong Wang; Chengshui Chen
Journal:  Clin Transl Med       Date:  2017-05-16

10.  Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.

Authors:  Wei Gao; Zhewei Tang; Yi-Fan Zhang; Mingqian Feng; Min Qian; Dimiter S Dimitrov; Mitchell Ho
Journal:  Nat Commun       Date:  2015-03-11       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.